AZD9833 China PK Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: ER+, HER2-, Metastatic Breast Cancer
Interventions: DRUG: AZD9833|DRUG: AZD9833|DRUG: AZD9833 with palbociclib|DRUG: AZD9833 with everolimus
Sponsor: AstraZeneca